The possible role of tumor necrosis factor-α in diabetic polyneuropathy

Experimental Diabesity Research

Volumn 4, Issue 2, 2003, Pages 65-71

  Satoh, Jo ^a   Yagihashi, Soroku ^b   Toyota, Takayoshi ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Diabetic neuropathy; Gliclazide; N acetylcysteine (NAC); TNF ; TNF promoter gene polymorphism; TNF suppressants; Troglitazone

Indexed keywords

ACETYLCYSTEINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; NICOTINAMIDE; ORAL ANTIDIABETIC AGENT; PENTOXIFYLLINE; STREPTOZOCIN; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CHRONIC DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER TOXICITY; MICROVASCULARIZATION; NERVE INJURY; NERVOUS TISSUE; NONHUMAN; PATHOGENESIS; PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; STREPTOZOCIN DIABETES;

EID: 0042828892     PISSN: 15438600     EISSN: None     Source Type: Journal    
DOI: 10.1155/EDR.2003.65     Document Type: Review

References (45)

1. Rabinovitch, A. (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes, 43, 613-621.
2. Hotamisligil, G. S., and Spiegelman, B. M. (1994) Tumor necrosis factor alpha: A key component of the obesity-diabetes link. Diabetes, 43, 1271-1278.
3. Vlassara, H. (1990) Chronic diabetic complications and tissue glycosylation. Relevant concern for diabetes-prone black population. Diabetes Care, 13, 1180-1185.
4. King, G. L., and Brownlee, M. (1996) The cellular and molecular mechanisms of diabetic complications. Endocrinol. Metab. Clin. North. Am., 25, 255-270.
5. Satoh, J., Seino, H., Abo, T., Tanaka, S., Shintani, S., Ohta, S., Tamura, K., Sawai, T., Nobunaga, T., Oteki, T., Kumagai, K., and Toyata, T. (1989) Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. J. Clin. Invest., 84, 1345-1348.
6. Tanaka, S., Seino, H., Satoh, J., Fujii, N., Rikiishi, H., Zhu, X. P., Takahashi, K., Sagara, M., Nobunaga, T., and Toyota, T. (1992) Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin. Immunol. Immunopathol., 62, 258-263.
7. Katsuki, A., Sumida, Y., Murashima, S., Murata, K., Takarada, Y., Ito, K., Fujii, M., Tsuchihashi, K., Goto, H., Nakatani, K., and Yano, Y. (1998) Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab., 83, 859-862.
8. Morohoshi, M., Fujisawa, K., Uchimura, I., and Numano, F. (1996) Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes, 45, 954-959.
9. Mendez, C., Garcia, I., and Maier, R. V. (1996) Oxidants augment endotoxin-induced activation of alveolar macrophages. Shock, 6, 157-163.
10. Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A., and Pasagian, A. (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science, 240, 1546-1548.
11. Fernandez-Real, J. M., and Ricart, W. (1999) Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia, 42, 1367-1374.
12. Peraldi, P., Hotamisligil, G. S., Buurman, W. A., White, M. F., and Spiegelman, B. M. (1996) Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J. Biol. Chem., 271, 13018-13022.
13. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., and Spiegelman, B. M. (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest., 95, 2409-2415.
14. Ferro, T. J., Gertzberg, N., Selden, L., Neumann, P., and Johnson, A. (1997) Endothelial barrier dysfunction and p42 oxidation induced by TNF-alpha are mediated by nitric oxide. Am. J. Physiol., 272(5 Pt 1), L979-L988.
15. Samad, F., Uysal, K. T., Wiesbrock, S. M., Pandey, M., Hotamisligil, G. S., and Loskutoff, D. J. (1999) Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl. Acad. Sci. U.S.A., 96, 6902-6907.
16. Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Willette, R. N., Lysko, P. G., and Feuerstein, G. Z. (1997) Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke, 28, 1233-1244.
17. Meager, A. (1999) Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev., 10, 27-39.
18. Otsuki, M., Hashimoto, K., Morimoto, Y., Kishimoto, T., and Kasayama, S. (1997) Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes, 46, 2096-2101.
19. Satoh, J., Qiang, X., Sagara, M., and Toyota, T. (1998) Treatment of diabetic neuropathy with antioxidants/TNF-α suppressants. Gendaiiryo, 30, 55-62 (Japanese).
20. Sagara, M., Satoh, J., Wada, R., Yagihashi, S., Takahashi, K., Fukuzawa, M., Muto, G., Muto, Y., and Toyota, T. (1996) Inhibition with N-acetylcysteine of development of peripheral neuropathy in streptozotocin-induced diabetic rats. Diabetologia, 39, 263-269.
21. Qiang, X., Satoh, J., Sagara, M., Fukuzawa, M., Masuda, T., Miyaguchi, S., Takahashi, K., and Toyota, T. (1998) Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metabolism, 47, 977-981.
22. Qiang, X., Satoh, J., Sagara, M., Fukuzawa, M., Masuda, T., Sakata, Y., Muto, G., Muto, Y., Takahashi, K., and Toyota, T. (1998) Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia, 41, 1321-1326.
23. Qiang, X., Satoh, J., Sagara, M., Muto, G., Muto, Y., Miyaguchi, S., and Toyota, T. (1998) Treatment of diabetic neruropathy with pentoxifylline. Tounyoubyou, Supple 1, 378 (Japanese).
24. Sen, C. K. (1998) Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem. Pharmacol., 55, 1747-1758.
25. Peristeris, P., Clark, B. D., Gatti, S., Faggioni, R., Mantovani, A., Mengozzi, M., Orencole, S. F., Sironi, M., and Ghezzi, P. (1992) N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell. Immunol., 140, 390-399.
26. Sagara, M., Satoh, J., Zhu, X.-P., Takahashi, K., Fukuzawa, M., Muto, G., Muto, Y., and Toyota T. (1994) Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats. Clin. Immunol. Immunopathol., 71, 333-337.
27. Fukuzawa, M., Satoh, J., Muto, G., Muto, Y., Nishimura, S., Miyaguchi, S., Qiang, X. L., and Toyota, T. (1997) Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-α. Immunol. Lett., 59, 7-11.
28. Fukuzawa, M., Satoh, J., Sagara, M., Muto, G., Muto, Y., Nishimura, S., Miyaguchi, S., Qiang, X. L., Sakata, Y., Nakazawa, T., Ikehata, F., Ohta, S., and Toyota, T. (1997) Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-α in-vitro and in-vivo. Immunopharmacology, 36, 49-55.
29. Fukuzawa, M., Satoh, J., Ohta, S., Takahashi, K., Miyaguchi, S., Qiang, X., Sakata, Y., Nakazawa, T., Takizawa, Y., and Toyota, T. (2000) Modulation of tumor necrosis factor-α production with anti-hypertensive drugs. Immunopharmacology, 48, 65-74.
30. Fukuzawa, M., Satoh, J., Qiang, X., Miyaguchi, S., Sakata, Y., Nakazawa, T., Ikehata, F., Ohta, S., and Toyata, T. (1999) Inhibition of tumor necrosis factor-α with anti-diabetic agents. Diabetes Res. Clin. Pract., 43, 147-154.
31. Malik, R. A., Williamson, S., Abbott, C., Carrington, A. L., Iqbal, J., Schady, W., and Boulton, A. J. (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human, diabetic neuropathy: Randomised double-blind controlled trial. Lancet, 352, 1978-1981.
32. Mandell, G. L. (1995) Cytokines, phagocytes, and pentoxifylline J. Cardiovasc. Pharmacol., 25 (Suppl 2), S20-S22.
33. Carrington, A. L., and Litchfield, J. E. (1999) The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: A critical review for the end of the 20th century. Diabetes Rev., 7, 275-299.
34. Iwata, T., Sato, S., Jimenez, J., McGowan, M., Moroni, M., Dey, A., Ibaraki, N., Reddy, V. N., and Carper, D. (1999) Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J. Biol. Chem., 274, 7993-8001.
35. Magnuson, D. K., Maier, R. V., and Pohlman, T. H. (1989) Protein kinase C: A potential pathway of endothelial cell activation by endotoxin, tumor necrosis factor, and interleukin-1. Surgery, 106, 216-223.
36. Igarashi, M., Wakasaki, H., Takahara, N., Ishii, H., Jiang, Z. Y., Yamauchi, T., Kuboki, K., Meier, M., Rhodes, C. J., and King, G. L. (1999) Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J. Clin. Invest., 103, 185-195.
37. Munoz-Fernandez, M. A., and Fresno, M. (1998) The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol., 56, 307-340.
38. Sima, A. A., and Sugimoto, K. (1999) Experimental diabetic neuropathy: An update. Diabetologia, 42, 773-788.
39. Creange, A., Barlovatz-Meimon, G., and Gherardi, R. K. (1997) Cytokines and peripheral nerve disorders. Eur. Cytokine Netw., 8, 145-151.
40. Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., and Duff, G. W. (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A., 94, 3195-3199.
41. Allen, R. D. (1999) Polymorphism of the human TNF alpha promoter - random variation or functional diversity? Mol. Immunol., 36, 1017-1027.
42. Hawrami, K., Hitman, G. A., Rema, M., Snehalatha, C., Viswanathan, M., Ramachandran, A., and Mohan, V. (1996) An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Human Immunol., 46, 49-54.
43. Higuchi, T., Seki, N., Kamizono, S., Yamada, A., Kimura, A., Kato, H., and Itoh, K. (1998) Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens, 51, 605-612.
44. Housai, T., Bando, S., Takahashi, K., Negoro, K., Takizawa, Y., Ohta, S., Sekikawa, A., Hirai, M., Hinokio, Y., Suzuki, S., Satoh, J., and Toyota, T. (2001) Association of TNF-α promoter polymorphism C(-857)T with F-wave latency as an early marker of diabetic polyneuropathy in type 2 diabetic patients. Diabetes, (Suppl 2), A186.
45. Satoh, J., Watanabe, T., Yagihashi, S., Tsuji, I., and Toyota, T. (2001) Diabetic survey: The questionnaire of 30,000 diabetic patients in the Tohoku area in Japan, In: Diabetic Neuropathy; Polyol Pathway and Recent Advance, Edited by Matsuoka, K., Hotta, N., and Yagihashi, S., pp. 293-300. Tokyo, Gendaiiryosya (Japanese).